Related Experiment Video
Updated: Aug 13, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Pharmaceutical co-crystals
Peddy Vishweshwar1, Jennifer A McMahon, Joanna A Bis
1Department of Chemistry, University of South Florida, CHE205, Tampa, 33620, USA.
Abstract:
Crystal engineering has evolved in such a manner that it is now synonymous with the paradigm of supramolecular synthesis, that is, it invokes self-assembly of existing molecules to generate a wide range of new solid forms without the need to break or form covalent bonds. This review addresses how crystal engineering has been applied to active pharmaceutical ingredients, API's, with emphasis upon how pharmaceutical co-crystals, a long known but little explored alternative to the four traditionally known forms of API, can be generated in a rational fashion. Case studies on Carbamazepine (CBZ) and Piracetam are presented which illustrate the relative ease with which pharmaceutical co-crystals can be prepared and their diversity in terms of composition and physical properties.
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Crystal Growth: Principles of Crystallization
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent – the...
Production of Pharmaceuticals
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

